Echinacoside
Based on 21 publication(s) in Google Scholar
Echinacoside, one of the phenylethanoids isolated from the stems of Cistanche deserticola, effectively inhibits Wnt/β-catenin signaling. Echinacoside elicits neuroprotection by activating Trk receptors and their downstream signal pathways. Antiosteoporotic activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.71%
- No. CAS: 82854-37-3
- Fòrmula: C35H46O20
- Peso molecular:786.73
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Echinacoside
More- Gut. 2025 Oct 7:gutjnl-2025-336374. [Abstract]
- Autophagy. 2025 Oct 25. [Abstract]
- Cell Mol Biol Lett. 2022 Oct 12;27(1):92. [Abstract]
- Phytomedicine. 2026 Jun:155:158100. [Abstract]
- Phytomedicine. 2025 Nov 25:148:157378. [Abstract]
- Free Radic Biol Med. 2026 Jul:250:436-452. [Abstract]
- Cell Prolif. 2025 Oct;58(10):e70044. [Abstract]
- Eur J Pharmacol. 2025 Oct 15:1005:178092. [Abstract]
- Int Immunopharmacol. 2023 Jul:120:110279. [Abstract]
- J Cell Mol Med. 2022 Nov;26(21):5414-5425. [Abstract]
- J Cell Mol Med. 2021 Jan;25(1):203-216. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9767-9776. [Abstract]
- Neurotox Res. 2026 Mar 19;44(2):12. [Abstract]
- Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Oct;1870(7):159681. [Abstract]
- Chem Biol Drug Des. 2024 Sep;104(3):e14616. [Abstract]
- Immunopharmacol Immunotoxicol. 2022 Dec;44(6):850-859. [Abstract]
- J Neurosci Res. 2019 Dec;97(12):1689-1705. [Abstract]
- PeerJ. 2024 Apr 9:12:e17229. [Abstract]
- J Mol Histol. 2025 Nov 24;57(1):4. [Abstract]
- Biochem Biophys Res Commun. 2020 May 21;526(1):170-175. [Abstract]
- SSRN. 2026 Mar 20.
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
IHC
-
WB
-
WB
Actividad biológica
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fifty-six aged 6 months female Sprague-Dawley rats (OVX rat model)[3]
-
Dosage:30, 90, 270 mg/kg body weight
-
Administration:p.o.; daily for 12 weeks
-
Result:The increases of body weight, serum hydroxyproline (HOP) levels, and the decreases of uterus wet weight and BMD were significantly reversed.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 82854-37-3
-
Appearance Solid
-
Peso molecular 786.73
-
Fòrmula C35H46O20
-
Color White to yellow
-
SMILES
OC1=CC(/C=C/C(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](OCCC4=CC(O)=C(O)C=C4)O[C@@H]2CO[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)=O)=CC=C1O
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Gut
Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma. [Abstract]2025 Oct 7:gutjnl-2025-336374. PMID: 41057233
Echinacoside purchased from MedChemExpress. Usage Cited in: Gut. 2025 Oct 7:gutjnl-2025-336374. [Abstract]
Cell viability of (A) HepG2 and (B) LO2 cells incubated with different concentrations of Echinacoside ( ECH; 0, 1, 2, 5, 10, or 20 μg/mL) for 0, 12, 24, and 48 h.
Echinacoside purchased from MedChemExpress. Usage Cited in: Gut. 2025 Oct 7:gutjnl-2025-336374. [Abstract]
HepG2 cell survival and tumor volume. Xenograft mice 4 weeks (4-week-old BALB/c nude mice; HepG2 cells ) post-injection with Echinacoside (ECH; 5 mg/kg/day; i.v.), AMPG (5 mg/kg/day), or ECH@AMPG (5 mg/kg/day) after tumor formation for 1 week for 4 weeks.
Echinacoside purchased from MedChemExpress. Usage Cited in: Gut. 2025 Oct 7:gutjnl-2025-336374. [Abstract]
TUNEL analysis showed increased HepG2 cell apoptosis in ECH-treated mice. Xenograft mice 4 weeks (4-week-old BALB/c nude mice; HepG2 cells ) post-injection with Echinacoside (ECH; 5 mg/kg/day; i.v.), AMPG (5 mg/kg/day), or ECH@AMPG (5 mg/kg/day) after tumor formation for 1 week for 4 weeks.
Echinacoside purchased from MedChemExpress. Usage Cited in: Gut. 2025 Oct 7:gutjnl-2025-336374. [Abstract]
Xenograft mouse tumors showing UBR5, AXIN1, LDHA, PKM2, Survivin, C-myc, and β-catenin expression. Xenograft mice 4 weeks (4-week-old BALB/c nude mice; HepG2 cells ) post-injection with Echinacoside (ECH; 5 mg/kg/day; i.v.), AMPG (5 mg/kg/day), or ECH@AMPG (5 mg/kg/day) after tumor formation for 1 week for 4 weeks.
-
Autophagy
XIAP-ULK1-Mediated mitophagy modulates carnitine metabolism to mitigate diabetic kidney disease. [Abstract]2025 Oct 25. PMID: 41139215 -
Cell Mol Biol Lett
Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery. [Abstract]2022 Oct 12;27(1):92. PMID: 36224534 -
Phytomedicine
Echinacoside modulates PARP14-GLUD1 axis to mediate energy metabolism reprogramming and mitochondrial function in diminished ovarian reserve. [Abstract]2026 Jun:155:158100. PMID: 41895093 -
Phytomedicine
Cistanche deserticola extract and its active components, echinacoside, ameliorate sarcopenia by activating the IGF-1/PI3K-AKT pathway to modulate ferroptosis. [Abstract]2025 Nov 25:148:157378. PMID: 41106096 -
Free Radic Biol Med
Echinacoside improves antioxidant responses and angiogenesis through Parkin-MFN2-mediated mitophagy to promote diabetic wound healing. [Abstract]2026 Jul:250:436-452. PMID: 41962601 -
Cell Prolif
Revitalising Aging Oocytes: Echinacoside Restores Mitochondrial Function and Cellular Homeostasis Through Targeting GJA1/SIRT1 Pathway. [Abstract]2025 Oct;58(10):e70044. PMID: 40251808 -
Eur J Pharmacol
Echinacoside mitigates sepsis-associated encephalopathy by inhibiting STING pathway and reducing neuroinflammation. [Abstract]2025 Oct 15:1005:178092. PMID: 40885235 -
Int Immunopharmacol
Echinacoside ameliorates 5-fluorouracil-induced endothelial injury and senescence through SIRT1 activation. [Abstract]2023 Jul:120:110279. PMID: 37187128 -
J Cell Mol Med
Echinacoside inhibited cardiomyocyte pyroptosis and improved heart function of HF rats induced by isoproterenol via suppressing NADPH/ROS/ER stress. [Abstract]2022 Nov;26(21):5414-5425. PMID: 36201630 -
J Cell Mol Med
Echinacoside reverses myocardial remodeling and improves heart function via regulating SIRT1/FOXO3a/MnSOD axis in HF rats induced by isoproterenol. [Abstract]2021 Jan;25(1):203-216. PMID: 33314649 -
Naunyn Schmiedebergs Arch Pharmacol
Echinacoside activates Nrf2/PPARγ signaling pathway to modulate mitochondrial fusion-fission balance to ameliorate ox-LDL-induced dysfunction of coronary artery endothelial cells. [Abstract]2024 Dec;397(12):9767-9776. PMID: 38916831 -
Neurotox Res
Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]2026 Mar 19;44(2):12. PMID: 41854817 -
Biochim Biophys Acta Mol Cell Biol Lipids
Echinacoside suppresses macrophage lipid accumulation and attenuates atherosclerosis via the MDM2/PPARγ/ABCA1 signaling axis. [Abstract]2025 Oct;1870(7):159681. PMID: 40819820 -
Chem Biol Drug Des
Echinacoside Alleviates Carbon Tetrachloride-Induced Chronic Liver Injury by Modulating the NF-κB/NLRP3 Inflammasome Pathway. [Abstract]2024 Sep;104(3):e14616. PMID: 39245793 -
Immunopharmacol Immunotoxicol
Echinacoside alleviates osteoarthritis in rats by activating the Nrf2-HO-1 signaling pathway. [Abstract]2022 Dec;44(6):850-859. PMID: 35815581 -
J Neurosci Res
Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein. [Abstract]2019 Dec;97(12):1689-1705. PMID: 31420910 -
PeerJ
The role of echinacoside-based cross-linker nanoparticles in the treatment of osteoporosis. [Abstract]2024 Apr 9:12:e17229. PMID: 38618561 -
J Mol Histol
Echinacoside ameliorates bleomycin-induced idiopathic pulmonary fibrosis by regulating macrophage polarization. [Abstract]2025 Nov 24;57(1):4. PMID: 41284091 -
Biochem Biophys Res Commun
Echinacoside inhibits breast cancer cells by suppressing the Wnt/β-catenin signaling pathway. [Abstract]2020 May 21;526(1):170-175. PMID: 32201078
Echinacoside purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2020 May 21;526(1):170-175. [Abstract]
Echinacoside inhibits the expression of key Wnt/b-catenin proteins in breast cancer cell lines. MDA-MB-231 and MDA-MB-468 cells are treated with the indicated concentrations of Echinacoside for 24 h. Cells are harvested, and proteins are extracted using RIPA cell lysis buffer.
Echinacoside purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2020 May 21;526(1):170-175. [Abstract]
Echinacoside inhibits the expression of key Wnt/b-catenin proteins in breast cancer cell lines. MDA-MB-231 and MDA-MB-468 cells are treated with the indicated concentrations of Echinacoside for 24 h. LEF1, CD44, and cyclin D1 protein expression levels are detected by western blot.
-
Solvente y solubilidad
DMSO : 100 mg/mL (127.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 35.71 mg/mL (45.39 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (127.11 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Li X, et al. Echinacoside ameliorates D-galactosamine plus lipopolysaccharide-induced acute liver injury in mice via inhibition of apoptosis and inflammation. Scand J Gastroenterol. 2014 Aug;49(8):993-1000. [Content Brief]
[2]. Tang C, et al. Echinacoside inhibits breast cancer cells by suppressing the Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 2020 Mar 19. pii: S0006-291X(20)30530-1. [Content Brief]
[3]. Li F, et al. Antiosteoporotic activity of echinacoside in ovariectomized rats. Phytomedicine. 2013 Apr 15;20(6):549-57. [Content Brief]
[4]. Zhang D, et al. Echinacoside inhibits amyloid fibrillization of HEWL and protects against Aβ-induced neurotoxicity. Int J Biol Macromol. 2014 Sep 2;72C:243-253. [Content Brief]
[5]. Zhu M, et al. Transient exposure to echinacoside is sufficient to activate Trk signaling and protect neuronal cells from rotenone. J Neurochem. 2013 Feb;124(4):571-80. [Content Brief]
[6]. Li F, et al. Echinacoside promotes bone regeneration by increasing OPG/RANKL ratio in MC3T3-E1 cells. Fitoterapia. 2012 Dec;83(8):1443-50. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.2711 mL | 6.3554 mL | 12.7108 mL | 31.7771 mL |
| 5 mM | 0.2542 mL | 1.2711 mL | 2.5422 mL | 6.3554 mL | |
| 10 mM | 0.1271 mL | 0.6355 mL | 1.2711 mL | 3.1777 mL | |
| 15 mM | 0.0847 mL | 0.4237 mL | 0.8474 mL | 2.1185 mL | |
| 20 mM | 0.0636 mL | 0.3178 mL | 0.6355 mL | 1.5889 mL | |
| 25 mM | 0.0508 mL | 0.2542 mL | 0.5084 mL | 1.2711 mL | |
| 30 mM | 0.0424 mL | 0.2118 mL | 0.4237 mL | 1.0592 mL | |
| 40 mM | 0.0318 mL | 0.1589 mL | 0.3178 mL | 0.7944 mL | |
| DMSO | 50 mM | 0.0254 mL | 0.1271 mL | 0.2542 mL | 0.6355 mL |
| 60 mM | 0.0212 mL | 0.1059 mL | 0.2118 mL | 0.5296 mL | |
| 80 mM | 0.0159 mL | 0.0794 mL | 0.1589 mL | 0.3972 mL | |
| 100 mM | 0.0127 mL | 0.0636 mL | 0.1271 mL | 0.3178 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.